← Back to Clinical Trials
Recruiting NCT05874362

NCT05874362 People Bereaved by Violent Death : Negative Event Biases and Temporal Perception

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05874362
Status Recruiting
Phase
Sponsor Hôpital le Vinatier
Condition Post Traumatic Stress Disorder
Study Type INTERVENTIONAL
Enrollment 61 participants
Start Date 2023-09-19
Primary Completion 2026-09-19

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 65 Years
Study Type INTERVENTIONAL
Interventions
Diagnosis of depressive episode or post traumatic stress disorderNo diagnosis of depressive episode or post traumatic stress disorder

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 61 participants in total. It began in 2023-09-19 with a primary completion date of 2026-09-19.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

A violent death is defined by its brutality, unexpectedness and is secondary to an external cause (suicide, homicide, accident). Bereavement following a violent death constitutes a particular clinical situation, at risk of complications. Research on bereavement after a violent death shows higher risks of psychiatric and somatic complications than in bereavement by non-violent death. These complications, sometimes comorbid, take the form of depressive episodes, post-traumatic stress disorders, suicidal behavior and prolonged grief disorders after 12 months, precociously mediated by ruminations. Processes responsible for this increased risk of complications are poorly documented. Current literature relates mainly to socio-demographic and epidemiological factors which, alone, do not explain this difference in risks. Further research is needed exploring other kinds of data and processes. To our knowledge, there is no description of early neurocognitive functioning in people bereaved after violent death. This study aims at exploring early neurocognitive processes which can lead to complications in people bereaved by violent death.

Eligibility Criteria

Inclusion Criteria: * An age between 18 and 65 years old * Recent bereavement by violent death of a relative in first and second degree Exclusion Criteria: * Protected adults * Lack of mastering French language * History of neurodegenerative disorder * History of psychiatric disorder treated pharmacologically with modification of the basic treatment in the month preceding the death * The take of an benzodiazepine treatment in the 24th hours before the first visit (T0)

Contact & Investigator

Central Contact

Laurene LESTIENNE

✉ laurene.lestienne@ch-le-vinatier.fr

📞 0033437915120

Principal Investigator

Edouard LEAUNE

PRINCIPAL INVESTIGATOR

Vinatier Hospital

Frequently Asked Questions

Who can join the NCT05874362 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Post Traumatic Stress Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05874362 currently recruiting?

Yes, NCT05874362 is actively recruiting participants. Contact the research team at laurene.lestienne@ch-le-vinatier.fr for enrollment information.

Where is the NCT05874362 trial being conducted?

This trial is being conducted at Bron, France.

Who is sponsoring the NCT05874362 clinical trial?

NCT05874362 is sponsored by Hôpital le Vinatier. The principal investigator is Edouard LEAUNE at Vinatier Hospital. The trial plans to enroll 61 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology